PROCEPT BioRobotics Corporation reported significant financial growth in its latest quarterly filing, with revenues reaching $83.3 million for the three months ended September 30, 2025, a 43% increase from $58.4 million in the same period last year. For the nine months ending September 30, 2025, total revenue was $231.7 million, up 48% from $156.3 million in the prior year. The company’s gross profit also saw a substantial rise, totaling $54.0 million for the third quarter and $149.9 million for the nine-month period, reflecting gross margins of 65% for both periods, compared to 63% and 60% respectively in the previous year.
Despite the revenue growth, PROCEPT BioRobotics reported a net loss of $21.4 million for the third quarter, slightly higher than the $21.0 million loss recorded in the same quarter of 2024. For the nine-month period, the net loss decreased to $65.7 million from $72.6 million year-over-year. The increase in operating expenses, particularly in selling, general, and administrative costs, which rose by 38% to $59.0 million in the third quarter, contributed to the ongoing losses. This increase was partly due to accelerated stock-based compensation expenses related to the retirement of the former CEO.
The company has made strategic advancements, including the FDA clearance of its next-generation HYDROS Robotic System in August 2024, which is expected to enhance its market position in the urology sector. As of September 30, 2025, PROCEPT had an installed base of 835 robotic systems globally, with 653 located in the United States. The company aims to expand its market share by increasing the adoption of its Aquablation therapy among urologists, targeting approximately 2,700 hospitals that perform resective BPH procedures.
Operationally, PROCEPT BioRobotics is focused on increasing system utilization and expanding its sales force to drive further adoption of its technologies. The company reported a significant increase in sales of handpieces and consumables, which rose by 54% to $49.7 million in the third quarter. The company’s cash and cash equivalents stood at $294.3 million as of September 30, 2025, providing a solid financial foundation for ongoing investments in research and development, as well as sales and marketing efforts.
Looking ahead, PROCEPT BioRobotics anticipates continued revenue growth driven by increased system placements and utilization of its robotic systems. The company is committed to enhancing its product offerings and expanding its market presence, while also managing costs to improve gross margins. The management believes that existing cash reserves and anticipated revenue will be sufficient to meet capital requirements for at least the next twelve months, although they acknowledge the potential need for additional financing to support future growth initiatives.
About PROCEPT BioRobotics Corp
Procept Biorobotics develops advanced surgical robotic systems for minimally invasive urologic procedures, primarily treating benign prostatic hyperplasia (BPH). Its flagship products, AquaBeam and HYDROS systems, utilize proprietary waterjet technology for precise, safe, and durable tissue removal. The company targets hospitals and urologists worldwide, emphasizing clinical evidence, personalized treatment planning, and broad reimbursement support to improve patient outcomes and establish a new standard in BPH surgery.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.